BeOne Medicines Director Xiaodong Wang Exercises Options and Sells $13.4M in ADS via 10b5-1 Plan

Insider Filing Analysis: BeOne Medicines Ltd. (NASDAQ: ONC)

Overview

On September 10, 2026, Xiaodong Wang, Director and Chair of the Scientific Advisory Board at BeOne Medicines Ltd., reported the exercise of stock options and subsequent sale of American Depositary Shares (ADSs) on September 8, 2026, totaling approximately $13.37 million.

Key Transaction Details

• Derivative Exercise: Exercised 403,351 stock options (with an exercise price of $2.84 per ordinary share, expiring November 15, 2026), converting into 31,027 ADSs (ratio: 1 ADS = 13 Ordinary Shares).
• Dispositions (Sales):
  • Sold an existing direct holding of 7,260 ADSs at weighted average prices ranging from $345.38 to $348.01.
  • Sold the 31,027 ADSs acquired through the option exercise at weighted average prices ranging from $348.31 to $351.25.
  • Total ADSs Sold: 38,287 shares for total proceeds of $13,366,091.80.
• Plan: Transactions were effected pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on June 9, 2026.

Post-Transaction Holdings

• Direct ADSs: 0 ADSs remaining.
• Direct Ordinary Shares: 4,588,113 Ordinary Shares.
• Indirect Ordinary Shares: 4,978,213 Ordinary Shares held across family trusts, Wang Investment LLC, and spouse.
• Derivative Holdings: 1,210,079 stock options remaining directly.

Market Significance

This transaction represents a scheduled option monetization ahead of the November 2026 option expiration, conducted entirely under a Rule 10b5-1 trading plan. The insider retains substantial equity ownership in the issuer through direct and indirect ordinary shareholdings.